Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Neurology  |  Rheumatology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (27) clinical trials

Systemic Sclerosis (SSc) is a devastating and often life threatening illness predominantly affecting women characterized by autoimmunity, widespread microvascular disease, and fibrosis, especially of the skin, gastrointestinal tract, and lung. Multiple studies have shown evidence of platelet activation in SSc. Chronic intermittent vasospasm in the microvasculature combined with platelet aggregation ...

Phase N/A

Participation in this study would last approximately 96 weeks and would include approximately 12 visits to our office. Compensation may be provided for time and travel


The study will determine how well the treatment with the study drug called nintedanib can demonstrate a slowing in the rate of lung scarring (or fibrosis) and how well the study treatment has an effect on the skin thickening.


High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early Rapidly Progressive Diffuse Systemic Sclerosis

- Systemic sclerosis (scleroderma; SSc) is a rare, disfiguring systemic disorder characterized by fibrosis of the skin and visceral organs that alters every aspect of an individual life - Although some features of scleroderma phenotype are well established and represent the hallmarks of the disease, the primary cause is not ...


Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis

Elevated serum brain natriuretic peptide (BNP) levels released from myocytes of ventricles upon stretch have been found in patients with isolated right ventricular (RV) pressure overload. However, limited data suggest that serum BNP may be elevated in patients with systemic sclerosis (SSc), especially with RV dysfunction. The aim of this ...

Phase N/A

Platelet Gel in Systemic Sclerosis

- Systemic sclerosis (scleroderma; SSc) is a connective tissue disease characterized by a progressive fibrosis of the skin and visceral organs. - A diffuse cutaneous microvascular damage occurs in 30-50% of patients, often leading to digital ulcers development, responsible for pain, functional disability, disfiguring scars, digital bony reabsorption, infection and ...


Duke Autoimmunity in Pregnancy Registry

Women with a systemic autoimmune disease that would be followed by a rheumatologist will be included in this study. All women will be seen every 4-6 weeks throughout pregnancy. At each visit, women will complete a questionnaire, the physician will determine the current level of disease activity, and a blood ...

Phase N/A

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Low-dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: a Phase II pilot study. Background and rationale Systemic sclerosis (SSc; scleroderma) is a rare, multisystem connective tissue disease characterised by widespread microvascular lesions and by the increased deposition of matrix components in the skin and internal organs, with varying ...


Pulmonary Arterial Hypertension in Systemic Sclerosis

The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis. To evaluate the role of BNP in this setting.To analyze data recorded with respect to the parameters commonly used for SSc evaluation ...

Phase N/A

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

PRIMARY OBJECTIVES: I. To determine the safety and potential efficacy of reduced intensity conditioning with fludarabine/cyclophosphamide/low-dose total body irradiation (TBI) and allogeneic hematopoietic cell transplantation (HCT) for the stabilization or regression of disease manifestations of severe systemic sclerosis (SSc). SECONDARY OBJECTIVES: I. To determine whether stable allogeneic donor engraftment can ...